SMARCB1 and neoplasm: For this, we made use of a GR activity score (explained above) and the lung adenocarcinoma dataset from TCGA (91/877 tumours harboured SWI/SNF mutations; SMARCB1 18.09%; SMARCC2 9.52%, SMARCD2 6.66%, SMARCD3 1.90%, ARID1A 29.52%, ARID2 31.42%, SMARCE1 2.85%).